Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (9)
- Genetic Phenomena (5)
- Medical Sciences (5)
- Pediatrics (5)
- Analytical, Diagnostic and Therapeutic Techniques and Equipment (4)
-
- Chemicals and Drugs (4)
- Public Health (4)
- Amino Acids, Peptides, and Proteins (3)
- Cardiovascular Diseases (3)
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)
- Oncology (3)
- Therapeutics (3)
- Anatomy (2)
- COVID-19 (2)
- Hematology (2)
- Neoplasms (2)
- Pathological Conditions, Signs and Symptoms (2)
- Surgical Procedures, Operative (2)
- Forensic Science and Technology (1)
- Health Services Administration (1)
- Hemic and Immune Systems (1)
- Immune System Diseases (1)
- Inorganic Chemicals (1)
- Legal Studies (1)
- Musculoskeletal Diseases (1)
- Orthopedics (1)
- Patient Safety (1)
- Keyword
-
- Hemophagocytic lymphohistiocytosis (2)
- Sickle cell disease (2)
- Acute chest syndrome (1)
- Bypassing agent (1)
- COVID-19 (1)
-
- Copper (1)
- Disseminated infection (1)
- Disseminated intravascular coagulation (1)
- Factor VIII inhibitor (1)
- Fever of unknown origin (1)
- Hemoglobinopathy (1)
- Hemophilia (1)
- Hlh-2004 protocol (1)
- Hyperinflammatory state (1)
- Immune system dysregulation (1)
- Immunosuppression (1)
- Intensive care (1)
- Neonatal herpes simplex (1)
- Neutropenia (1)
- Osteoarthritis (1)
- Osteonecrosis (1)
- Pancytopenia (1)
- Secondary hemophagocytic lymphohistiocytosis (hlh) (1)
- Sideroblastic anemia (1)
- Total hip arthroplasty (1)
- Transfusions (1)
- Zinc (1)
- Zinc-induced hypocupremia (1)
Articles 1 - 18 of 18
Full-Text Articles in Hemic and Lymphatic Diseases
Presentation, Diagnosis, And Acute Treatment Of Secondary Hemophagocytic Lymphohistiocytosis: A Case Report, Alexandra Bartholomew, Michael Connick, Catherine Loehr, Shane Sanne
Presentation, Diagnosis, And Acute Treatment Of Secondary Hemophagocytic Lymphohistiocytosis: A Case Report, Alexandra Bartholomew, Michael Connick, Catherine Loehr, Shane Sanne
School of Medicine Faculty Publications
Secondary hemophagocytic lymphohistiocytosis (HLH) is a rare, immunologically driven disorder with a high mortality rate. It is typically diagnosed on the basis of clinical and laboratory criteria. We present the case of a 53-year-old woman with multiple previous hospitalizations for fever of unknown origin and fatigue. Her workup ultimately led to a diagnosis of HLH. We discuss the presentation, diagnostic criteria, and clinical treatment of secondary HLH to guide workup and management for future patients affected by this rare disease.
Debunking Myths: Sickle Cell Trait, Crises & Sudden Death, Michael R. Debaun, Corey J. Hebert, Yvette Marie Miller
Debunking Myths: Sickle Cell Trait, Crises & Sudden Death, Michael R. Debaun, Corey J. Hebert, Yvette Marie Miller
School of Medicine Faculty Publications
No abstract provided.
Outcomes In Patients With Classic Hodgkin Lymphoma Refractory Or Intolerant To Brentuximab Vedotin And Anti-Pd-1 Therapy: A Real World Analysis From 15 U.S. Academic Centers, Timothy J. Voorhees, Eric M. Mclaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish Ayyappan, Lauren Shea, Matt Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal Desai, Praveen Ramakrishnan Geethakumari, Mehdi Hamadani, Natalie Grover, Narendranath Epperla
Outcomes In Patients With Classic Hodgkin Lymphoma Refractory Or Intolerant To Brentuximab Vedotin And Anti-Pd-1 Therapy: A Real World Analysis From 15 U.S. Academic Centers, Timothy J. Voorhees, Eric M. Mclaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish Ayyappan, Lauren Shea, Matt Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal Desai, Praveen Ramakrishnan Geethakumari, Mehdi Hamadani, Natalie Grover, Narendranath Epperla
School of Medicine Faculty Publications
Anti-PD-1 based therapies and brentuximab vedotin (BV) have significantly improved survival in patients with classic Hodgkin lymphoma (cHL) and have been incorporated into earlier lines of therapy. However, there is insufficient data regarding the clinical outcomes in patients who develop refractory disease or who become intolerant of BV and anti-PD-1 therapies (double refractory/intolerant; DR/INT). Here, we evaluated outcomes in patients with DR/INT cHL from 15 US academic medical centers. A total of 173 patients were identified as DR/INT. The median overall survival from the time of cHL diagnosis (OS-1) was 14.8 years (95% CI: 10.9–20.9 years) and the 10-year OS-1 …
Case Report: Disseminated Herpes Simplex Virus Complicated By Hemophagocytic Lymphohistiocytosis In A Neonate, Nicholas Tadros, Nihal Godiwala
Case Report: Disseminated Herpes Simplex Virus Complicated By Hemophagocytic Lymphohistiocytosis In A Neonate, Nicholas Tadros, Nihal Godiwala
School of Medicine Faculty Publications
Neonatal herpes simplex virus (HSV) infection carries a high mortality rate due to its potential to cause disseminated disease involving multiple organ systems, which can rapidly progress to shock and death if not promptly treated. In rare cases, neonates may mount an uncontrolled inflammatory response leading to hemophagocytic lymphohistiocytosis (HLH), a severe hyperinflammatory syndrome. We present a case of neonatal HSV infection complicated by HLH, highlighting the challenges of managing both conditions concurrently. Our therapeutic approach demonstrated a reduction in systemic inflammation and viral load; however, despite these efforts, the patient developed multiorgan failure and ultimately died from the initial …
Hematopoietic Cell Transplant Compared With Standard Care In Adolescents And Young Adults With Sickle Cell Disease, Mark C. Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K. Waller, John E. Levine, John J. Strouse, Joseph H. Antin, Suhag H. Parikh, Nitya Bakshi, Carlton D Dampier, Jennifer J. Jaroscak, Shayla Bergmann, Trish E. Wong, Vamsi K. Kota, Betty Sue Pace, Lazaros J. Lekakis, Premal D. Lulla, Robert Nickel, Kimberly A. Kasow, Uday R. Popat, Wally R. Smith, Lolie C. Yu, Nancy L. Difronzo, Nancy L. Geller, Naynesh Kamani, Elizabeth Sue Klings, Kathryn Hassell, Adam M. Mendizabal, Et Al
Hematopoietic Cell Transplant Compared With Standard Care In Adolescents And Young Adults With Sickle Cell Disease, Mark C. Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K. Waller, John E. Levine, John J. Strouse, Joseph H. Antin, Suhag H. Parikh, Nitya Bakshi, Carlton D Dampier, Jennifer J. Jaroscak, Shayla Bergmann, Trish E. Wong, Vamsi K. Kota, Betty Sue Pace, Lazaros J. Lekakis, Premal D. Lulla, Robert Nickel, Kimberly A. Kasow, Uday R. Popat, Wally R. Smith, Lolie C. Yu, Nancy L. Difronzo, Nancy L. Geller, Naynesh Kamani, Elizabeth Sue Klings, Kathryn Hassell, Adam M. Mendizabal, Et Al
School of Medicine Faculty Publications
Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2-years after biologic assignment to a Donor or No Donor (SOC) Arm based on the availability of an HLA-matched sibling or unrelated donor (BMTCTN 1503; NCT02766465). A donor search was commenced after eligibility confirmation. The primary endpoint was the comparison of survival 2 years after biologic assignment between treatment arms. Power calculations required 60 participants on the Donor Arm and 140 on the No Donor Arm to determine if early transplant-related mortality might be balanced …
Physician Perspectives About The Diagnosis And Management Of Acute Chest Syndrome, Neha Bhasin, Dana Marie Leblanc, Sean Yates, Quentin Eichbaum, An Pham, Deva Sharma, Li Zhang, Elliott P. Vichinsky, Ravi Sarode
Physician Perspectives About The Diagnosis And Management Of Acute Chest Syndrome, Neha Bhasin, Dana Marie Leblanc, Sean Yates, Quentin Eichbaum, An Pham, Deva Sharma, Li Zhang, Elliott P. Vichinsky, Ravi Sarode
School of Medicine Faculty Publications
Background: Acute chest syndrome (ACS) is the leading cause of mortality, accounting for 25% of all deaths among individuals with sickle cell disease (SCD). There is a lack of evidence-based laboratory and clinical risk stratification guidelines for the diagnosis and management of ACS. Study Design and Methods: To better understand physician practices for the management of ACS in the United States, we created an ACS Working Group including hematology and transfusion medicine physicians from four different SCD treatment centers in the United States. The working group created a physician survey that included physician demographics and ACS diagnostic criteria that they …
Asymptomatic Covid-19-Associated Acquired Hemophilia A And Disseminated Intravascular Coagulation From A Bypassing Agent, Abraham Attah, Deanna Huffman, Palash Asawa, Vinay Edlukudige Keshava, Deep Shah
Asymptomatic Covid-19-Associated Acquired Hemophilia A And Disseminated Intravascular Coagulation From A Bypassing Agent, Abraham Attah, Deanna Huffman, Palash Asawa, Vinay Edlukudige Keshava, Deep Shah
School of Medicine Faculty Publications
Acquired hemophilia A (AHA) is a clotting disorder characterized by the presence of neutralizing antibodies that inhibit factor VIII, resulting in increased bleeding risk. Known etiologies include malignancy, autoimmune conditions, graft-vs-host disease, and more recently coronavirus disease 2019 (COVID-19) infection. In this case report, we describe an 86-year-old female who was found to have AHA incidentally during preoperative workup for meningioma resection. She was subsequently found to have COVID-19 infection which was the likely cause of her development of AHA. She was treated with factor eight inhibitor bypassing agent (FEIBA) and recombinant factor VII (rVII) for a small hematoma on …
Zinc-Containing Over-The-Counter Product Causing Sideroblastic Anemia And Neutropenia, Marshall Patrick Stagg, Jennifer Miatech, Baseera Majid, Ravali Polala
Zinc-Containing Over-The-Counter Product Causing Sideroblastic Anemia And Neutropenia, Marshall Patrick Stagg, Jennifer Miatech, Baseera Majid, Ravali Polala
School of Medicine Faculty Publications
Sideroblastic anemia is characterized by anemia, granulocytopenia, and bone marrow findings of vacuolated precursors and ringed sideroblasts. Zinc-induced copper deficiency can present as sideroblastic anemia and neutropenia. We report the case of a previously healthy 74-year-old female who presented with newly discovered sideroblastic anemia as a result of an over-the-counter oral vitamin and mineral supplement. Serum analysis revealed increased zinc levels, decreased copper levels, and a decrease in ceruloplasmin. Bone marrow evaluation revealed ringed sideroblasts and cytoplasmic vacuolization in myeloid precursors. She demonstrated improvement in her hematologic profile with discontinuation of the over-the-counter product and administration of oral copper supplementation. …
Effects Of Covid-19 Vaccination On Pro-Coagulant State Of A Protein S-Deficient Pediatric Patient: New Hope For Treatment Of The Deficiency, Diana Polania-Villanueva, M. Kumar, Lekha Thangada, Jone Garai, Jovanny Zabaleta, Rinku Majumder
Effects Of Covid-19 Vaccination On Pro-Coagulant State Of A Protein S-Deficient Pediatric Patient: New Hope For Treatment Of The Deficiency, Diana Polania-Villanueva, M. Kumar, Lekha Thangada, Jone Garai, Jovanny Zabaleta, Rinku Majumder
School of Medicine Faculty Publications
ISTH 2023 Congress, June 24 - 28, 2023, Montreal, Canada
Factors Associated With Thrombo-Hemorrhagic Deaths In Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide And All-Trans Retinoic Acid, C. Singh, U. Yanamandra, P. Karunakaran, N. Jindal, S. Kumar, N. Saini, A. Jandial, A. Jain, D. Lad, G. Prakash, A. Khadwal, S. Naseem, Narender Kumar, J. Ahluwalia, N. Varma, S. Varma, P. Malhotra
Factors Associated With Thrombo-Hemorrhagic Deaths In Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide And All-Trans Retinoic Acid, C. Singh, U. Yanamandra, P. Karunakaran, N. Jindal, S. Kumar, N. Saini, A. Jandial, A. Jain, D. Lad, G. Prakash, A. Khadwal, S. Naseem, Narender Kumar, J. Ahluwalia, N. Varma, S. Varma, P. Malhotra
School of Medicine Faculty Publications
ISTH 2023 Congress, June 24 - 28, 2023, Montreal, Canada
Antiphosphatidylserine/Prothrombin Antibodies In Childhood Sle Are Associated With Lupus Anticoagulant Positivity, S. Chugh, R. Pilania, A. Kler, C. Hans, Narender Kumar, S. Singh, J. Ahluwalia
Antiphosphatidylserine/Prothrombin Antibodies In Childhood Sle Are Associated With Lupus Anticoagulant Positivity, S. Chugh, R. Pilania, A. Kler, C. Hans, Narender Kumar, S. Singh, J. Ahluwalia
School of Medicine Faculty Publications
ISTH 2023 Congress, June 24 - 28, 2023, Montreal, Canada
Pb0550 Novel Variants Of Pros1 Gene Related To Protein S Deficiency, A. Malik, M. Kumar, V. Pereira, Jovanny Zabaleta, Rinku Majumder
Pb0550 Novel Variants Of Pros1 Gene Related To Protein S Deficiency, A. Malik, M. Kumar, V. Pereira, Jovanny Zabaleta, Rinku Majumder
School of Medicine Faculty Publications
ISTH 2023 Congress June 24-28, 2023, Montreal, Canada
Unearthing The Genotype-Inhibitor Phenotype Association In Severe Hemophilia A: A North Indian Cohort Study, D. Ray, Narender Kumar, C. Hans, A. Kler, R. Sharma, M. Jamwal, H. Kishan Sene, R. Thakur, M. Singh, P. Bhatia, D. Bansal, A. Jain, P. Malhotra, J. Ahluwalia, R. Das
Unearthing The Genotype-Inhibitor Phenotype Association In Severe Hemophilia A: A North Indian Cohort Study, D. Ray, Narender Kumar, C. Hans, A. Kler, R. Sharma, M. Jamwal, H. Kishan Sene, R. Thakur, M. Singh, P. Bhatia, D. Bansal, A. Jain, P. Malhotra, J. Ahluwalia, R. Das
School of Medicine Faculty Publications
ISTH 2023 Congress June 24-28, 2023, Montreal, Canada
Pb0559 Novel Variants Of Pros1 Gene Related To Protein S Deficiency, A. Malik, M. Kumar, Jovanny Zabaleta, Rinku Majumder
Pb0559 Novel Variants Of Pros1 Gene Related To Protein S Deficiency, A. Malik, M. Kumar, Jovanny Zabaleta, Rinku Majumder
School of Medicine Faculty Publications
ISTH 2023 Congress June 24-28, 2023, Montreal, Canada
Pbo575 Novel Variants Of Pros1 Gene Related To Protein S Deficiency, A. Malik, Diana Polania-Villanueva, M. Kumar, Jone Garai, Jovanny Zabaleta, Rinku Majumder
Pbo575 Novel Variants Of Pros1 Gene Related To Protein S Deficiency, A. Malik, Diana Polania-Villanueva, M. Kumar, Jone Garai, Jovanny Zabaleta, Rinku Majumder
School of Medicine Faculty Publications
ISTH 2023 Congress June 24-28, 2023, Montreal, Canada
Regulation Of Protein S Gene Expression By Hypoxia Inducible Factor 1 Α And Estrogen Receptor, Mohammad Mohammad, V. Pilli, M. Kumar, Alaina Guilbeau, Narender Kumar, Rinku Majumder
Regulation Of Protein S Gene Expression By Hypoxia Inducible Factor 1 Α And Estrogen Receptor, Mohammad Mohammad, V. Pilli, M. Kumar, Alaina Guilbeau, Narender Kumar, Rinku Majumder
School of Medicine Faculty Publications
ISTH 2023 Congress June 24-28, 2023, Montreal, Canada
Protein S Antibody As An Adjunct Therapy For Hemophilia B, Hope P. Wilson, Aliyah Pierre, Ashley L. Paysse, Narender Kumar, Brian C. Cooley, Pratyadipta Rudra, Adrianne W. Dorsey, Diana Polania-Villanueva, Sabyasachi Chatterjee, Maissaa Janbain, Maria C. Velez, Rinku Majumder
Protein S Antibody As An Adjunct Therapy For Hemophilia B, Hope P. Wilson, Aliyah Pierre, Ashley L. Paysse, Narender Kumar, Brian C. Cooley, Pratyadipta Rudra, Adrianne W. Dorsey, Diana Polania-Villanueva, Sabyasachi Chatterjee, Maissaa Janbain, Maria C. Velez, Rinku Majumder
School of Medicine Faculty Publications
ABSTRACT: Hemophilia B (HB) is caused by an inherited deficiency of plasma coagulation factor IX (FIX). Approximately 60% of pediatric patients with HB possess a severe form of FIX deficiency (< 1% FIX activity). Treatment typically requires replacement therapy through the administration of FIX. However, exogenous FIX has a limited functional half-life, and the natural anticoagulant protein S (PS) inhibits activated FIX (FIXa). PS ultimately limits thrombin formation, which limits plasma coagulation. This regulation of FIXa activity by PS led us to test whether inhibiting PS would extend the functional half-life of FIX and thereby prolong FIX-based HB therapy. We assayed clotting times and thrombin generation to measure the efficacy of a PS antibody for increasing FIX activity in commercially obtained plasma and plasma from pediatric patients with HB. We included 11 pediatric patients who lacked additional comorbidities and coagulopathies. In vivo, we assessed thrombus formation in HB mice in the presence of the FIXa ± PS antibody. We found an accelerated rate of clotting in the presence of PS antibody. Similarly, the peak thrombin formed was significantly greater in the presence of the PS antibody, even in plasma from patients with severe HB. Furthermore, HB mice injected with PS antibody and FIX had a 4.5-fold higher accumulation of fibrin at the thrombus induction site compared with mice injected with FIX alone. Our findings imply that a PS antibody would be a valuable adjunct to increase the effectiveness of FIX replacement therapy in pediatric patients who have mild, moderate, and severe HB.
Hemoglobinopathy Is Associated With Total Hip Arthroplasty Indication Even Beyond Sickle Cell Anemia, Maxwell J. Rakutt, Daniel N. Bracey, Anna Cohen-Rosenblum, Peter K. Sculco, Franco M. Sabatini, Cale A. Jacobs, Stephen T. Duncan, David C. Landy
Hemoglobinopathy Is Associated With Total Hip Arthroplasty Indication Even Beyond Sickle Cell Anemia, Maxwell J. Rakutt, Daniel N. Bracey, Anna Cohen-Rosenblum, Peter K. Sculco, Franco M. Sabatini, Cale A. Jacobs, Stephen T. Duncan, David C. Landy
School of Medicine Faculty Publications
Background: The extent to which hemoglobinopathies other than sickle anemia (HbSS) are associated with hip osteonecrosis is unknown. Sickle cell trait (HbS), hemoglobin SC (HbSC), and sickle/β-thalassemia (HbSβTh) may also predispose to osteonecrosis of the femoral head (ONFH). We sought to compare the distributions of indications for a total hip arthroplasty (THA) in patients with and without specific hemoglobinopathies. Methods: PearlDiver, an administrative claims database, was used to identify 384,401 patients aged 18 years or older undergoing a THA not for fracture from 2010 to 2020, with patients grouped by diagnosis code (HbSS N = 210, HbSC N = 196, …